Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of ClinicalThought™ commentaries!
How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.
Here’s my take on why some of the key reasons biosimilars may be an attractive cost-cutting measure in cancer care also pose a challenge to their widespread adoption.
Herein, I summarize recent biosimilar approvals as well as how these agents might affect patient care and counseling in oncology practice.
Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112
Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.